The research also showed that VVM patients had a significantly shorter survival than CM patients when treated with immune-oncology therapies. "These therapies are front-line in melanoma treatment, but our findings suggest that they are not very effective in this subtype," Wilhite said. "The research tells us that new therapeutic ....